Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors [NA]
A clinical trial update describing a study on implementing lifestyle-based survivorship care plans for lymphoma survivors.
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies [Phase 1]
A Phase 1 clinical trial evaluating UB-VV111 with and without rapamycin for relapsed/refractory CD19+ B-cell malignancies is currently recru…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
This update describes a real-world data and sample collection study in frail or heavily pretreated diffuse large B-cell lymphoma patients, c…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: DALY II Japan/MB-CART2019.1 for DLBCL [Phase 2]
A Phase 2 trial (DALY II Japan/MB-CART2019.1) by Miltenyi Biomedicine is evaluating MB-CART2019.1 for diffuse large B-cell lymphoma in Japan…
-
CLINICAL_TRIALS research · 2026-01-08Clinical Trial Update: Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma [Phase 1]
A Phase 1 study of KITE-197 for relapsed or refractory diffuse large B-cell lymphoma is currently active and not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Copanlisib Plus Venetoclax in R/R DLBCL [Phase 1, Phase 2]
A Phase 1/Phase 2 study conducted by the Dana-Farber Cancer Institute is evaluating the combination of copanlisib and venetoclax in relapsed…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL [Phase 2]
A phase 2 clinical trial is evaluating the feasibility and clinical efficacy of atezolizumab as consolidation therapy in high-risk diffuse l…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) [Phase 2]
A Phase II trial tests rituximab with CC-99282 as front-line therapy for older frail patients with diffuse large B-cell lymphoma. The study,…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells [NA]
This update describes an ongoing study that monitors circulating tumor DNA in real time and analyzes prognostic factors in patients with Dif…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. [Phase 2]
This multicenter Phase II study evaluates a ctDNA- and PET-guided therapy approach in patients with diffuse large B-cell lymphoma. The trial…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)
A recruiting clinical study evaluating whether a pragmatic geriatric assessment before CAR-T cell therapy or bispecific antibody treatment c…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency [NA]
A Mayo Clinic-sponsored clinical trial evaluates cholecalciferol (vitamin D3) for improving survival in patients with newly diagnosed cancer…
-
CLINICAL_TRIALS research · 2025-12-30Clinical Trial Update: Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 trial is evaluating the combination of copanlisib and nivolumab in patients with Richter's transformation or transformed indolent …
-
CLINICAL_TRIALS research · 2025-12-29Clinical Trial Update: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma
A recruiting clinical trial investigating how MYC aberrations and the tumor microenvironment affect diffuse large B-cell lymphoma and high-g…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies [NA]
This clinical trial compares reduced-dose apixaban and rivaroxaban against low-molecular-weight heparin for venous thromboembolism managemen…
-
CLINICAL_TRIALS research · 2025-12-26Clinical Trial Update: Randomised Controlled Trial of Artificial Intelligence-assisted Health Education [NA]
A randomized controlled trial to assess the effectiveness of artificial intelligence–assisted health education, sponsored by Zhongnan Hospit…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance [Phase 2]
Clinical trial update describing a Phase 2 study of combining ibrutinib with R-CHOP followed by ibrutinib maintenance for diffuse large B-ce…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. [Phase 1]
This is a Phase 1 dose-escalation and expansion study evaluating intratumoral ONM-501 alone and in combination with cemiplimab in patients w…
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL [Phase 2]
Phase 2 study evaluating acalabrutinib in combination with rituximab for untreated, elderly and/or frail patients with diffuse large B-cell …
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study of GF-CART01, a CD20/CD19 CAR T cell therapy, evaluating safety and early activity in a…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial evaluating circulating tumor DNA (ctDNA) testing in people with diffuse large B-cell lymphoma and related high-grade …
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma [NA]
This clinical trial update describes the use of nanochip technology to monitor treatment response and detect relapse in participants with di…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) [Phase 1, Phase 2]
A Phase 1/2 clinical trial update assessing the safety and tolerability of tafasitamab alone or in combination with other drugs in Japanese …
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Long-term Study to Evaluate Safety and Persistence of GF-CART01
This clinical trial update describes a long-term safety and persistence study of GF-CART01, with enrollment not yet starting.
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating a triple combination of tafasitamab, retifanlimab, and rituximab with standard therapy for diffuse lar…